Specific disease areas are you addressing at the moment ?
We are working on palliative care and pain management -- especially cancer pain , sciatica and fibromyalgia . Cannabinoids have the potential to replace opioids in chronic pain management , which we feel is the reason the government should pay particular attention to promoting this particular therapeutic pathway .
Other focus areas include neurological disorders , particularly insomnia , migraine , Parkinson ' s ; dermatological diseases ; female reproductive system dysregulations and gastrointestinal inflammatory disorders .
What is the significance of olypharmacology in drug discovery ? Latest trends in the segment ?
Sometimes , unwittingly or by design , India becomes a pioneer in adopting novel approaches . This is evident in India ' s space program , India ' s nuclear program , in the development of Digital Public Goods , to name a few . Similarly , India , at least with respect to the pharma regulatory framework , is a leader in polypharmacology . This is because since 2015 , India has had a phytopharmaceutical regulatory regime a perfect blend of classical and modern medicine , which recognises
“ Cannabinoids have the potential to replace opioids in chronic pain management .”
the synergistic activity of several agents / compounds acting on multiple targets to deliver higher treatment efficacy . It is incumbent on India ' s biopharmaceutical sector to leverage the opportunity this phyto-regulatory regime allows to create modern , polycompound medicines with proven safety and efficacy . The onus in this instance is on the private sector and not on government .
Your outlook for the company and the sector in the next 5 years ?
We are confident of being a global leader in phytomedicine in years to come . We are working on mission mode to achieve this goal , and are confident that India is the best country to enable our vision of promoting health and healing .
We also think the medical cannabis industry globally will change substantially , as more and more firms emulate the methods we are pioneering at Savikalpa Sciences and join efforts to shift the narrative away from " medical cannabis " to " cannabinoid medicine " that can be administered to cannabis-naive patients at home or in a clinical setting , minus the minor yet prevalent side effects of intoxication associated with cannabis .
BioTech
BIOVOICENEWS . COM 29